Announcements
- Clearmind Medicine Advances its Proprietary Psychedelic- Based Synthetic Alcohol Beverage Product
- Clearmind Medicine Secures Exclusive Global Rights to Breakthrough Psychedelic Compounds for PTSD Treatment
- Clearmind Applies to Cease Being a Reporting Issuer in Canada
- Clearmind Medicine Announces Exclusive Licensing Agreement for Generation 3.0 Psychedelic Compounds for the Treatment of Mental Disorders
- Clearmind Medicine Files U.S. Patent Application for Psychedelic-Based Treatment for Eating Disorders
- Clearmind Medicine CEO Issues Letter to Shareholders
- Clearmind Medicine Announces International Patent Application for Preventing and Treating Depression
- Breakthrough in Wellness: Clearmind Medicine's Psychedelic Treatment Granted Divisional Patent Approval in China
- Clearmind Medicine Obtains Clearance for its Psychedelic- Based Alcoholism Clinical Trial
- Clearmind Medicine Received Approval for a Voluntary Delisting of its Common Shares From the Canadian Securities Exchange
More ▼
Key statistics
As of last trade, Clearmind Medicine Inc (CWY0:DEU) traded at 0.957, 963.33% above the 52 week low of 0.09 set on Nov 28, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.9635 |
---|---|
High | 0.978 |
Low | 0.933 |
Bid | 0.9445 |
Offer | 0.9725 |
Previous close | 0.942 |
Average volume | 400.00 |
---|---|
Shares outstanding | 3.17m |
Free float | 3.17m |
P/E (TTM) | -- |
Market cap | 3.39m USD |
EPS (TTM) | -30.92 USD |
Data delayed at least 15 minutes, as of Jun 07 2024.
More ▼